The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Items 601–700 of 1,000
Nguyen, T. T., Dao, T., Nguyen, H. T., Park, J.-H., Jeong, S.-J., Kim, S., Jo, Y., Thieu, N. T. H., Zhao, J., Ding, F., et al. (2026) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2656 · Cited by 23
Park, M. G., Cho, D.-Y., Yeo, J. K., Cho, S. I., Jung, J., Yang, S., Kong, D.-H., Ha, J. K., & Kim, J.-D. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.184269 · Cited by 23
Traish, A. M. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00174.2016 · Cited by 23
Testosterone therapy and prostate cancer
Pastuszak, A. W., Rodríguez, K. M. G., Nguyen, T. M., & Khera, M. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.08.17 · Cited by 23
Leydig cell aging: Molecular mechanisms and treatments
Papadopoulos, V., & Zirkin, B. R. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.023 · Cited by 24
Sex differences in preclinical models of hypertension
Olivera, S., & Graham, D. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00770-1 · Cited by 23
Hypopituitarism in the elderly
Antonopoulou, M., Sharma, R. K., Farag, A., Banerji, M. A., & Karam, J. G. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.05.002 · Cited by 23
Scientific overview of hormone treatment used for rejuvenation
Morley, J. E. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.009 · Cited by 23
Grossmann, M., Anawalt, B. D., & Wu, F. C. W. (2014) · Clinical Endocrinology · doi:10.1111/cen.12594 · Cited by 23
Elsherbiny, A., Tricomi, M., Bhatt, D., & Dandapantula, H. K. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0838-x · Cited by 23
Yatsu, T., Kusakabe, T., Kato, K., Inouye, Y., Nemoto, K., & Kanno, Y. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00748 · Cited by 26
Miner, M. M., Morgentaler, A., Khera, M., & Traish, A. M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13589 · Cited by 23
Haring, R., Xanthakis, V., Coviello, A., Sullivan, L., Bhasin, S., Wallaschofski, H., Murabito, J. M., & Vasan, R. S. (2012) · International Journal of Andrology · doi:10.1111/j.1365-2605.2012.01285.x · Cited by 22
Self-citationIrrational Exuberance in Testosterone Prescribing: When Will the Bubble Burst?
Handelsman, D. J. (2015) · Medical Care · doi:10.1097/mlr.0000000000000416 · Cited by 22
Dias, J. P., Shardell, M. D., Carlson, O. D., Melvin, D., Caturegli, G., Ferrucci, L., Chia, C. W., Egan, J. M., & Basaria, S. (2017) · Andrology · doi:10.1111/andr.12284 · Cited by 22
Self-citationSchooling, C. M., & Zhao, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-93360-z · Cited by 23
Sexual dimorphism in cardiac remodeling: the molecular mechanisms ruled by sex hormones in the heart
Ferreira, C., Trindade, F., Ferreira, R. M., Neves, J. S., Leite-Moreira, A. F., Amado, F. M. L., Santos, M., & Nogueira‐Ferreira, R. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02169-w · Cited by 23
Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations
Bhat, S. Z., & Dobs, A. S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.133 · Cited by 23
Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect
Tamargo, J. L., Pérez‐Villacastín, J., Caballero, R., & Delpón, E. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107077 · Cited by 22
Neonatal Testosterone Exposure Protects Adult Male Rats from Stroke
Persky, R., Liu, F., Xu, Y., Weston, G. K., Levy, S. J., Roselli, C. E., & McCullough, L. D. (2012) · Neuroendocrinology · doi:10.1159/000343804 · Cited by 22
Thrombosis in Three Postmenopausal Women Receiving Testosterone Therapy for Low Libido
Glueck, C. J., Bowe, D., Valdez, A., & Wang, P. (2013) · Women s Health · doi:10.2217/whe.13.31 · Cited by 22
Late onset hypogonadism of men is not equivalent to the menopause
Saad, F., & Gooren, L. J. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.06.016 · Cited by 22
Adverse Events Associated with Testosterone Administration
Shindel, A. (2011) · Yearbook of Urology · doi:10.1016/j.yuro.2010.12.025 · Cited by 22
Rais, M., Wilson, R. M., Urbanski, H. F., & Messaoudi, I. (2017) · GeroScience · doi:10.1007/s11357-017-9979-5 · Cited by 22
Testosterone replacement therapy and the risk of stroke in men: A systematic review
Loo, S. Y., Chen, B. Y., Yu, O. H. Y., Azoulay, L., & Renoux, C. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.08.013 · Cited by 22
Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients
Krishnan, V., Patel, N. J., MacKrell, J. G., Sweetana, S. A., Bullock, H. A., Ma, Y. L., Waterhouse, T., Yaden, B. C., Henck, J. W., Zeng, Q., et al. (2018) · Andrology · doi:10.1111/andr.12479 · Cited by 23
Testosterone, frailty and physical function in older men
Hsu, B., Cumming, R. G., & Handelsman, D. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1475227 · Cited by 22
Kaidonis, G., Rao, A. N., Ouyang, Y., & Stary, C. M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.08.001 · Cited by 22
Zaid, M. I. A., Dinh, P. C., Monahan, P. O., Fung, C., El-Charif, O., Feldman, D. R., Hamilton, R. J., Vaughn, D. J., Beard, C. J., Cook, R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7109 · Cited by 22
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Kırlangıç, O. F., Yilmaz‐Oral, D., Kaya‐Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., Khanam, A., Öztekin, Ç. V., & Gür, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.02.006 · Cited by 23
Men’s Health in Primary Care: An Emerging Paradigm of Sexual Function and Cardiometabolic Risk
Miner, M. M. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.09.003 · Cited by 21
Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis
Rezanezhad, B., Borgquist, R., Willenheimer, R. B., & Elzanaty, S. (2017) · The Aging Male · doi:10.1080/13685538.2017.1412422 · Cited by 21
Cardiovascular and metabolic actions of the androgens: Is testosterone a Janus-faced molecule?
Stallone, J. N., & Oloyo, A. K. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115347 · Cited by 22
Male hormonal contraception: Potential risks and benefits
Ilani, N., Swerdloff, R. S., & Wang, C. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9183-3 · Cited by 21
Velema, M. S., Kwa, B. H. B., & de Ronde, W. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32834e9001 · Cited by 21
Androgens and prostate disease
Page, S., & Cooper, L. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122361 · Cited by 22
Testosterone therapy in the new era of Food and Drug Administration oversight
Desroches, B. R., Kohn, T. P., Welliver, C., & Pastuszak, A. W. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.03.13 · Cited by 21
Hassan, J., & Barkin, J. (2016) · PubMed · Cited by 21
Dedov, I. I., Mel'nichenko, G. A., Rozhivanov, R. V., & Курбатов, Д. Г. (2017) · Problems of Endocrinology · doi:10.14341/probl201662678-80 · Cited by 21
Sullivan, S. D., Nash, M. S., Tefara, E., Tinsley, E. A., & Groah, S. L. (2017) · PM&R · doi:10.1016/j.pmrj.2017.08.404 · Cited by 21
Effects of testosterone and progressive resistance exercise on vascular function in older men
Hildreth, K. L., Schwartz, R. S., Griend, J. P. V., Kohrt, W. M., Blatchford, P. J., & Moreau, K. L. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00165.2018 · Cited by 21
Attenuation of frailty in older adults with mesenchymal stem cells
Florea, V., Bagno, L., Rieger, A. C., & Hare, J. M. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111120 · Cited by 21
Morimoto, M., Yamaoka, M., & Hara, T. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.563 · Cited by 21
Lundy, S. D., Parekh, N. V., & Shoskes, D. A. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.03.006 · Cited by 21
Wu, J., Hadoke, P. W. F., Mair, I., Lim, W. G., Miller, E., Denvir, M. A., & Smith, L. B. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu142 · Cited by 21
Testosterone replacement therapy and cardiovascular risk factors modification
Chahla, E. J., Hayek, M. E., & Morley, J. E. (2011) · The Aging Male · doi:10.3109/13685538.2010.541538 · Cited by 21
Testosterone replacement in men with sexual dysfunction
Lee, H., Hwang, E. C., Oh, C. K., Lee, S., Yu, H. S., Lim, J. S., Kim, H. W., Walsh, T. J., Kim, M. H., Jung, J. H., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013071.pub2 · Cited by 20
Khera, M., Torres, L. O., Grober, E. D., Morgentaler, A., Miner, M. M., Jones, T. H., Mills, J. N., & Salonia, A. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf036 · Cited by 21
Huang, G. T.-W., Bhasin, S., Pencina, K. M., Cheng, M., & Jasuja, R. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.09.011 · Cited by 20
Self-citationBuratto, J., Kirk, B., Phu, S., Vogrin, S., & Duque, G. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.013 · Cited by 20
Cruickshank, M., Hudson, J., Hernández, R. A., Aceves‐Martins, M., Quinton, R., Gillies, K., Aucott, L. S., Kennedy, C., Manson, P. D., Oliver, N. S., et al. (2024) · Health Technology Assessment · doi:10.3310/jryt3981 · Cited by 20
Sex steroids and cardiovascular disease
Yeap, B. B. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122357 · Cited by 20
Yang, X.-C., Wang, Y., Yan, S., Sun, L., Yang, G., Li, Y., & Yu, C. (2016) · Bioengineered · doi:10.1080/21655979.2016.1227141 · Cited by 20
Androgen and estrogen actions on male physical activity: a story beyond muscle
Jardí, F., Laurent, M. R., Dubois, V., Kim, N., Khalil, R., Decallonne, B., Vanderschueren, D., & Claessens, F. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0125 · Cited by 20
Marcelli, M., & Mediwala, S. N. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001233 · Cited by 23
Zitzmann, M., Cremers, J. F., Krallmann, C., & Kliesch, S. (2022) · The Aging Male · doi:10.1080/13685538.2022.2063830 · Cited by 20
Kozloski, M., Schumm, L. P., & McClintock, M. K. (2014) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbu123 · Cited by 20
Ariff, A. S. T., Soelaiman, I. N., Pramanik, J., & Shuid, A. N. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/818072 · Cited by 21
Selective androgen receptor modulators for the treatment of late onset male hypogonadism
Dalton, J. T., Coss, C. C., Jones, A., Hancock, M., & Steiner, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122339 · Cited by 22
Sood, A., Hosseinpour, A., Sood, A., Avula, S., Durrani, J., Bhatia, V., & Gupta, R. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.012 · Cited by 20
From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing
Fontaine, C., Gosset, A., Davezac, M., Buscato, M., Grouthier, V., Renault, M., Henrion, D., Trémollières, F., Schumacher, M., Lenfant, F., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf086 · Cited by 19
Population‐based patterns of prescription androgen use, 1976–2008
Hall, S. A., Ranganathan, G., TINSLEY, L. J., Lund, J. L., Kupelian, V. A., Wittert, G., Kantoff, P. W., Morales, Á., & de Araújo, A. B. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3579 · Cited by 19
Glintborg, D., Christensen, L. L., Kvorning, T., Larsen, R., Brixen, K., HOUGAARD, D. M., Richelsen, B., Bruun, J. M., & Andersen, M. (2013) · Mediators of Inflammation · doi:10.1155/2013/539156 · Cited by 20
Anabolic Steroids and Head Injury
Mills, J. D., Bailes, J. E., Turner, R. C., Dodson, S. C., Sakai, J., & Maroon, J. C. (2011) · Neurosurgery · doi:10.1227/neu.0b013e3182250918 · Cited by 19
Plasma testosterone is associated with Framingham risk score
Chock, B., Lin, T.-C., Li, C., & Swislocki, A. (2012) · The Aging Male · doi:10.3109/13685538.2011.654369 · Cited by 19
Testosterone Treatment of Older Men—Why Are Controversies Created?
Swerdloff, R. S., & Wang, C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2538 · Cited by 19
Subcellular effects of myocyte-specific androgen receptor overexpression in mice
Musa, M., Fernando, S. M., Chatterjee, D., & Monks, D. A. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0071 · Cited by 19
A Perspective on the Evolving Landscape in Male Reproductive Medicine
Bhasin, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3843 · Cited by 19
Self-citationYeap, B. B. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_50_17 · Cited by 19
Chen, F., Song, F., Chen, Y., Wang, Z., Li, Y., Liu, M., Li, Y., Song, M., Zhang, W., Zhao, J., et al. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.01.029 · Cited by 19
Gagliano‐Jucá, T., Li, Z., Pencina, K. M., Traustadóttir, T., Travison, T. G., Woodhouse, L. J., Basaria, S. S., Tsitouras, P. D., Harman, S. M., Bhasin, S., et al. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz167 · Cited by 22
Self-citationTestosterone, Diabetes Risk, and Diabetes Prevention in Men
Yeap, B. B., & Wittert, G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.004 · Cited by 19
Andropause: A review of the definition and treatment
Samaras, N., Frangos, E., Forster, A., Lang, P.-O., & Samaras, D. (2012) · European Geriatric Medicine · doi:10.1016/j.eurger.2012.08.007 · Cited by 19
Rasul, S., İlhan, A., Schernthaner-Reiter, M. H., Baumgartner-Parzer, S. M., & Kautzky‐Willer, A. (2011) · Gender Medicine · doi:10.1016/j.genm.2011.01.004 · Cited by 20
Gore, A. C., Hall, J. E., & Hayes, F. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00037-5 · Cited by 19
Morimoto, M., Amano, Y., Oka, M., Harada, A., Fujita, H., Hikichi, Y., Tozawa, R., Yamaoka, M., & Hara, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189480 · Cited by 20
Jasuja, G. K., & Rose, A. J. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4113-z · Cited by 19
Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale
Basaria, S. (2013) · Endocrine Practice · doi:10.4158/ep13318.ra · Cited by 18
Self-citationAndrogen Society Position Paper on Cardiovascular Risk With Testosterone Therapy
Morgentaler, A., Dhindsa, S., Dobs, A. S., Hackett, G. I., Jones, T. H., Kloner, R. A., Miner, M. M., Zitzmann, M., & Traish, A. M. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.008 · Cited by 18
Traish, A. M. (2023) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qead031 · Cited by 18
Lost in translation: challenges of current pharmacotherapy for sarcopenia
Tsai, S. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.016 · Cited by 19
Hisasue, S. (2015) · International Journal of Urology · doi:10.1111/iju.12880 · Cited by 18
Testosterone therapy and cardiovascular risk
Walsh, J. P., & Kitchens, A. C. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.014 · Cited by 19
Sattler, F. R. (2014) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000159 · Cited by 18
Testosterone Replacement Therapy in Reversing “Andropause”: What Is the Proof-of-Principle?
Lang, P. O., Samaras, D., & Samaras, N. (2012) · Rejuvenation Research · doi:10.1089/rej.2012.1316 · Cited by 18
Testosterone and cardiovascular disease – the controversy and the facts
Morgentaler, A., Feibus, A. H., & Baum, N. H. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.996111 · Cited by 19
Rastrelli, G., Giovannini, L., Calogero, A. E., Gianfrilli, D., Serra, E., Pizzocaro, A., Giagulli, V. A., Motta, G., Vancieri, G., Sperandio, A., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0461-5 · Cited by 18
Testosterone replacement therapy is associated with an increased risk of urolithiasis
McClintock, T. R., Valovska, M.-T. I., Kwon, N. K., Cole, A. P., Jiang, W., Kathrins, M. N., Bhojani, N., Haleblian, G. E., Koehlmoos, T. P., Haider, A. H., et al. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02726-6 · Cited by 18
Self-citationTestosterone Disorders and Male Hypogonadism in Kidney Disease
Garibotto, G., Esposito, P. B., Picciotto, D., & Verzola, D. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.006 · Cited by 18
Yelehe‐Okouma, M., Klein, M., Aridi, L. E., Maurier, A., Gillet, P., & Feigerlová, E. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12806 · Cited by 19
Relationships between endogenous and exogenous testosterone and cardiovascular disease in men
Thirumalai, A., & Anawalt, B. D. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09752-7 · Cited by 20
Diagnosis and Treatment of Low Testosterone among Patients with End‐Stage Renal Disease
Bao, Y., & Johansen, K. L. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12318 · Cited by 18
Matsumoto, A. M., & Bremner, W. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00019-8 · Cited by 18
UK policy statements on testosterone deficiency
Hackett, G. I., Kirby, M. G., Edwards, D., Jones, T. H., Rees, J., & Muneer, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12901 · Cited by 18
ARGALIOUS, M. Y., You, J., Mao, G., Ramos, D. J., Khanna, S. K., Maheshwari, K. K., & Trombetta, C. E. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001757 · Cited by 18
Matsumoto, A. M., & Bremner, W. J. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00019-5 · Cited by 18
Meikle, A. W. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.03.013 · Cited by 18
Alternatives to testosterone replacement: testosterone restoration
McCullough, A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.143736 · Cited by 18
Testosterone Deficiency, Cardiac Health, and Older Men
Hackett, G. I., Kirby, M. G., & Sinclair, A. J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/143763 · Cited by 17
Dedov, I. I., Mel'nichenko, G. A., Shestakova, M. V., Rozhivanov, R. V., Терехова, А. Л., Zilov, A. V., Ladygina, D. O., & Курбатов, Д. Г. (2017) · Obesity and metabolism · doi:10.14341/omet2017483-92 · Cited by 17
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
